NCT05916248View on ClinicalTrials.gov

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

Personalized neoantigen tumor vaccine

Neoantigen tumor vaccine

BIOLOGICAL

PD-1 inhibitor

pembrolizumab

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Xinpu BioTechnology Company Limited

UNKNOWN

lead

Ruijin Hospital

OTHER